Latest News
A fast-growing South Wales fintech company has closed a GBP1.25million funding round backed by Mercia Fund Managers, Development Bank of Wales and TTI Angels.
W2 Global Data, which is based in Newport and has doubled in size since the beginning of the year, is now planning to recruit a further 20 staff. The latest funding round follows an initial investment by Mercia and the development bank in 2017 and brings the total amount raised by the company to over GBP3.0million.
W2 provides identity verification services to help prevent fraud and money laundering. With access to thousands of government and
SHS Gesellschaft für Beteiligungsmanagement has held the first closing of its fifth fund with capital commitments of over EUR90 million.
The Tuebingen-based medical technology investor has now reached almost two thirds of the fund’s EUR150 million target.
The fifth generation of SHS funds will focus on the life sciences and medical technology sector with investments in 12-15 companies planned.
Around half of the investors in SHS V are already invested in the company’s previous funds.
“We would like to thank the investors for their trust in us,” says Hubertus Leonhardt, SHS partner and Managing Director responsible for
Giant Oak, a specialist in applying artificial intelligence, machine learning, and big data analytics for the security needs of government and industry, has secured a USD10 million investment from growth equity investor Edison Partners.
Proceeds will be used to fuel Giant Oak’s continued growth through expanding sales and marketing, software engineering, and behavioural science-based analytics for its proprietary search platform, Giant Oak Search Technology (GOST).
GOST was initially developed to screen the open, deep and dark web, and other data to help national security and law enforcement officials identify human trafficking, terrorist activities, and other security threats. GOST’s capabilities have
SANNE in Singapore has been appointed as Fund Administrator and Transaction Administrator for a new retail private equity bond issued by Astrea IV.
The successful launch of Astrea IV marked the first time that a bond backed by cash flows from a diversified portfolio of quality private equity fund investments was made available to retail investors. This deal will see SANNE working closely with the arranger of the deal, Azalea Asset Management Pte Ltd.
SANNE’s Chief Commercial Officer, Martin Schnaier, says: ‘This is a landmark achievement for SANNE and our Singapore business and we are delighted to be supporting
Weinberg Capital Partners (WCP) has held the final close of its WCP#3 buyout fund on 295 million euros only 10 months after going to market with an initial target of EUR250 million.
WCP#3 has received the support of its existing investors and new investors to almost double the size of the previous WCP#2 vintage.
In line with previous funds, WCP#3 aims to finance the growth of successful French SMEs, taking majority stakes, alongside management in LBO transactions on companies valued between EUR50 million and EUR200 million.
The fund focuses primarily on B2B and B2C distribution, business and health
UCL Technology Fund’s first investment to IPO has seen MeiraGTx Holdings, a clinical stage gene therapy company, raise USD75 million of gross proceeds from a public offering on 12 June.
MeiraGTx sold 5,000,000 shares at USD15.00 per share. The shares are listed on the Nasdaq Global Select Market.
The UCL Technology Fund (UCLTF) is managed by Albion Capital in collaboration with UCL Business (UCLB), UCL’s commercialisation company, and is dedicated to bringing UCL’s research in life and physical sciences to commercial reality. MeiraGTx is its first investment to IPO. MeiraGTx’s rare eye diseases business was borne out of the laboratories
Private equity and venture capital firm Insight Venture Partners (Insight) has held the close of its Fund X at USD6.3 billion, the firm’s largest to date.
The oversubscribed fund will be used to further its leading growth equity technology investment engine. With the close of the new fund, Insight has a total of over USD23 billion under management.
Since inception in 1995, Insight Venture Partners has seen its software-focused investment strategy drive increasing impact in the space. The firm has 150+ current portfolio companies, has overseen 225+ M&A transactions and has participated in more than 40 IPOs. In the
The latest MidCapMonitor prepared by the investment bank GCA Altium, which regularly analyses leveraged buyout finance transactions with a credit volume of between EUR20 million and EUR500 million, recorded a 48 per cent share of debt funds in the LBO market in the first half of 2018.
Debt funds successfully completed 22 transactions by the end of the first half of 2018, after having seen just 12 in the first six months of 2017. At this time in 2017, banks still held a 70 per cent market share, which has now shrunk to 52 per cent.
The success of
Edge Technology Group, a global technology advisory and fully-managed IT service provider catering for hedge funds, private equity firms and family offices worldwide, has been awarded the International Standard Organisation (ISO) 27001 certification for its information security systems’ infrastructure and operations supporting its Hong Kong based client offerings.
This recognition demonstrates Edge’s commitment to a reliable, adaptable, risk-based security program across its global organisation.
The ISO 27001 Certification is one of the most widely accepted and globally recognised security standards for organisations that identify, prevent and defend potential security vulnerabilities. Edge TG Hong Kong Limited is the latest Edge office to achieve ISO 27001
Scottish Biotech company Ryboquin has acquired Nanogenic Solutions, to form a new product and platform company, which, following acquisition will be named Nanogenics Limited.
Ryboquin raised GBP4.45 million in its third funding round from new and existing share-holders to finance the deal.
The combined company is set to revolutionise gene therapy by pioneering the safe, efficacious and regular dosing of all forms of gene therapy. Currently viruses and liposomes are used in this process, which have limited applications, severe side-effects and expensive technical problems. Nanogenics is developing LipTide, an artificial virus, which acts as a custom-built delivery system that
Special Reports
Featured
Events
12 November, 2026 – 8:00 am
12 November, 2026 – 5:00 pm
